Literature DB >> 16902772

Regulatory T cells in human autoimmune diseases.

Troy R Torgerson1.   

Abstract

In the most simplistic terms, immune tolerance can be envisioned as a balance with autoreactive cells that arise naturally in all individuals on one side and regulatory mechanisms designed to counter those autoreactive processes on the other. A tilt of the balance toward the autoreactive side, either by increasing the number or function of autoreactive cells or by diminishing regulatory mechanisms, is manifested as autoimmunity. In contrast, tilting of the balance toward increased regulation could conceivably cause immunodeficiency. Regulatory T cells (T(REG)), and particularly the naturally arising CD4(+)CD25(+) subset of T(REG) cells, provide a substantial component of the autoimmune counterbalance. The identification of forkhead box P3 (FOXP3) as a critical determinant of CD4(+)CD25(+) T(REG) development and function has provided new opportunities and generated expanded interest in studying the delicate balance between autoimmunity and regulatory mechanisms in human autoimmune diseases. Identification of both human and mouse syndromes in which FOXP3 is mutated, and consequently CD4(+)CD25(+) T(REG) cells are absent, has led to a rapid accumulation of knowledge regarding T(REG) development and function over the past 5 years. The recent development of antibody reagents to specifically identify CD4(+)CD25(+) T(REG) cells by their FOXP3 expression has provided new tools to identify these elusive cells and investigate their role in human disease. This review will focus on the current state of knowledge regarding the role of T(REG) in human autoimmune diseases and on specific human immunodeficiencies that provide interesting models of autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902772     DOI: 10.1007/s00281-006-0041-4

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  100 in total

1.  Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506).

Authors:  A Bousvaros; A M Leichtner; L Book; A Shigeoka; J Bilodeau; E Semeao; E Ruchelli; A E Mulberg
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

Review 2.  Clinical review 93: Autoimmune polyglandular syndrome type 1.

Authors:  C Betterle; N A Greggio; M Volpato
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

3.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.

Authors:  E Suri-Payer; A Z Amar; A M Thornton; E M Shevach
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

4.  Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome).

Authors:  Lutz Bindl; Troy Torgerson; Lucia Perroni; Nelly Youssef; Hans D Ochs; Olivier Goulet; Frank M Ruemmele
Journal:  J Pediatr       Date:  2005-08       Impact factor: 4.406

Review 5.  The genetic background of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy and its autoimmune disease components.

Authors:  Arndt Vogel; Christian P Strassburg; Petra Obermayer-Straub; Georg Brabant; Michael P Manns
Journal:  J Mol Med (Berl)       Date:  2002-02-05       Impact factor: 4.599

6.  Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.

Authors:  Mindi R Walker; Deborah J Kasprowicz; Vivian H Gersuk; Angele Benard; Megan Van Landeghen; Jane H Buckner; Steven F Ziegler
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

7.  CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis.

Authors:  Ismé M de Kleer; Lucy R Wedderburn; Leonie S Taams; Alka Patel; Hemlata Varsani; Mark Klein; Wilco de Jager; Gisela Pugayung; Francesca Giannoni; Ger Rijkers; Salvatore Albani; Wietse Kuis; Berent Prakken
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

Review 8.  Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways.

Authors:  F Rieux-Laucat; F Le Deist; A Fischer
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

9.  A new case of IPEX receiving bone marrow transplantation.

Authors:  E Mazzolari; C Forino; M Fontana; C D'Ippolito; A Lanfranchi; E Gambineri; H Ochs; R Badolato; L D Notarangelo
Journal:  Bone Marrow Transplant       Date:  2005-05       Impact factor: 5.483

10.  Omenn syndrome in an infant with IL7RA gene mutation.

Authors:  Silvia Giliani; Carmen Bonfim; Genevieve de Saint Basile; Gaetana Lanzi; Nicole Brousse; Adriana Koliski; Mariester Malvezzi; Alain Fischer; Luigi D Notarangelo; Francoise Le Deist
Journal:  J Pediatr       Date:  2006-02       Impact factor: 4.406

View more
  18 in total

1.  Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome.

Authors:  Laurence E Cheng; Bittoo Kanwar; Haig Tcheurekdjian; James P Grenert; Mica Muskat; Melvin B Heyman; Joseph M McCune; Diane W Wara
Journal:  Clin Immunol       Date:  2009-04-16       Impact factor: 3.969

2.  T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus.

Authors:  Matthew J Loza; A Shane Anderson; Kenneth S O'Rourke; James Wood; Islam U Khan
Journal:  Cell Immunol       Date:  2011-07-18       Impact factor: 4.868

3.  Frequency of Treg cells is reduced in CVID patients with autoimmunity and splenomegaly and is associated with expanded CD21lo B lymphocytes.

Authors:  Gururaj Arumugakani; Philip M D Wood; Clive R D Carter
Journal:  J Clin Immunol       Date:  2009-12-09       Impact factor: 8.317

Review 4.  Development of thymically derived natural regulatory T cells.

Authors:  Matthew L Bettini; Dario A A Vignali
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 5.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

6.  Regulatory T cells in type 1 diabetic patients with autoimmune chronic atrophic gastritis.

Authors:  Núria Alonso; María Jesús Martínez-Arconada; María Luisa Granada; Berta Soldevila; Ana Cantón; José Luis Mate; Anna Sanmartí; Eva María Martínez-Cáceres
Journal:  Endocrine       Date:  2009-03-17       Impact factor: 3.633

7.  Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells.

Authors:  Julie Rowin; Muthusamy Thiruppathi; Ebinehita Arhebamen; Jianrong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Muscle Nerve       Date:  2012-09       Impact factor: 3.217

8.  IL-12R beta 2 promotes the development of CD4+CD25+ regulatory T cells.

Authors:  Zhao Zhao; Shuo Yu; Denise C Fitzgerald; Mohamed Elbehi; Bogoljub Ciric; A M Rostami; Guang-Xian Zhang
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 9.  Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Bernadete Lourdes Liphaus; Adriana Almeida Jesus; Clovis Artur A Silva; João Bosco Oliveira; Maria Helena Kiss
Journal:  J Clin Immunol       Date:  2008-04-11       Impact factor: 8.317

Review 10.  T helper cell polarization in healthy people: implications for cardiovascular disease.

Authors:  Nels C Olson; Reem Sallam; Margaret F Doyle; Russell P Tracy; Sally A Huber
Journal:  J Cardiovasc Transl Res       Date:  2013-08-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.